1. Home
  2. SNTI vs IMRN Comparison

SNTI vs IMRN Comparison

Compare SNTI & IMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SNTI
  • IMRN
  • Stock Information
  • Founded
  • SNTI 2016
  • IMRN 1994
  • Country
  • SNTI United States
  • IMRN Australia
  • Employees
  • SNTI 48
  • IMRN N/A
  • Industry
  • SNTI Biotechnology: Pharmaceutical Preparations
  • IMRN Biotechnology: Pharmaceutical Preparations
  • Sector
  • SNTI Health Care
  • IMRN Health Care
  • Exchange
  • SNTI Nasdaq
  • IMRN Nasdaq
  • Market Cap
  • SNTI 18.2M
  • IMRN 15.0M
  • IPO Year
  • SNTI N/A
  • IMRN N/A
  • Fundamental
  • Price
  • SNTI $3.97
  • IMRN $1.96
  • Analyst Decision
  • SNTI Strong Buy
  • IMRN Strong Buy
  • Analyst Count
  • SNTI 1
  • IMRN 1
  • Target Price
  • SNTI $12.00
  • IMRN $5.00
  • AVG Volume (30 Days)
  • SNTI 7.2M
  • IMRN 6.0K
  • Earning Date
  • SNTI 11-14-2024
  • IMRN 12-31-2024
  • Dividend Yield
  • SNTI N/A
  • IMRN N/A
  • EPS Growth
  • SNTI N/A
  • IMRN N/A
  • EPS
  • SNTI N/A
  • IMRN N/A
  • Revenue
  • SNTI N/A
  • IMRN $3,271,194.00
  • Revenue This Year
  • SNTI $254.47
  • IMRN N/A
  • Revenue Next Year
  • SNTI $169.66
  • IMRN N/A
  • P/E Ratio
  • SNTI N/A
  • IMRN N/A
  • Revenue Growth
  • SNTI N/A
  • IMRN 171.67
  • 52 Week Low
  • SNTI $1.52
  • IMRN $1.59
  • 52 Week High
  • SNTI $16.94
  • IMRN $5.96
  • Technical
  • Relative Strength Index (RSI)
  • SNTI 47.37
  • IMRN 45.89
  • Support Level
  • SNTI $3.60
  • IMRN $2.05
  • Resistance Level
  • SNTI $5.96
  • IMRN $2.23
  • Average True Range (ATR)
  • SNTI 1.02
  • IMRN 0.17
  • MACD
  • SNTI -0.29
  • IMRN -0.00
  • Stochastic Oscillator
  • SNTI 5.74
  • IMRN 29.69

About SNTI Senti Biosciences Inc.

Senti Biosciences Inc is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with their gene circuit platform technologies to fight challenging diseases. The product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma.

About IMRN Immuron Limited

Immuron Ltd is a clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. The company's product, IMM-124E, is a proprietary immunomodulatory agent targeted at GI immune-mediated diseases including fatty liver diseases. The company functions in two segments namely, Research and Development and Hyperimmune products.

Share on Social Networks: